Home » Topics » Substance use and poisoning, BioWorld Science

Substance use and poisoning, BioWorld Science
RSS

Opiant Pharmaceuticals licenses heroin vaccine from WRAIR and NIDA

Nov. 3, 2016

Hawaii Biotech describes new Botulinum neurotoxin type A light chain inhibitors

Oct. 31, 2016

Omeros reports results from phase II study of PPARgamma agonist in cocaine use disorder

Oct. 20, 2016

U.K. Dstl gets funding to study inhaled ciprofloxacin in biodefense

Oct. 20, 2016

Addex initiates study of ADX-88178 in nonhuman primate model of cocaine addiction

Oct. 11, 2016

Phase II efficacy results for ABT-436 in alcohol-dependent subjects

Oct. 3, 2016

NIH dopamine D3 receptor antagonist VK-4-116 active in substance abuse models

Sep. 12, 2016

Insys Therapeutics enrolls first patient in phase II trial of canabidiol

Aug. 19, 2016

Promising phase III topline results for RBP-6000 monthly depot to treat opioid use disorder

Aug. 17, 2016

Embera Neurotherapeutics receives grant to continue development of drug for cocaine addition

July 27, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Regulatory actions for July 27, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Alfasigma,...